Lytic infection and transformation of cultured cells by JC virus (JCV) require five tumor proteins, which interact with factors regulating critical cellular processes. We demonstrate that JCV large T antigen (TAg) binds the F-box proteins β-transducin-repeat containing protein-1 and 2 (βTrCP1/2). These interactions involve a phosphodegron (DpSGX 2-4 pS) found in βTrCP substrates. TAg stability is unaltered, suggesting TAg is a pseudo-substrate. βTrCP and TAg co-localize in the cytoplasm, and a functional SCF complex is required. We examined whether TAg influences the levels of β-catenin, a βTrCP substrate. We were unable to demonstrate that TAg elevates β-catenin as previously reported, and a mutant TAg unable to bind βTrCP also had no detectable effect on β-catenin stability. Results presented in this study link JCV TAg to the cellular degradation complex, SCF βTrCP1/2 . Proteasomal degradation is essential for proper regulation of cellular functions, and interference with proteasomal pathways highlights possible JCV pathogenic and oncogenic mechanisms.
Introduction
JCV, a member of the Polyomaviridae family of viruses, causes asymptomatic infections in approximately 50% of the human population (Kean et al., 2009) . In immunocompromised individuals, the lytic destruction of oligodendrocytes by JCV leads to demyelination within the central nervous system and the fatal disease progressive multifocal leukoencephalopathy (PML). Inoculation of JCV into rodents and nonhuman primates results in tumor formation, and in humans JCV has been associated with brain, lung and colon tumors Khalili et al., 2006) . JCV produces five tumor proteins: Large T Antigen (TAg), small t Antigen (tAg), T′ 165 , T′ 136 and T′ 135 , which interact with several cellular proteins including tumor suppressors. The 5 tumor proteins bind differentially to members of the Retinoblastoma (Rb) family (Bollag et al., 2000 (Bollag et al., , 2006 (Bollag et al., , 2010 . Polyomavirus TAgs also interact with p53, inhibiting this tumor suppressor's transcriptional activity and increasing its stability, in part, by preventing its degradation via the E3 ubiquitin ligase, MDM-2 (reviewed in Levine, 2009 ). These events lead to cell cycle progression and contribute to the transforming potential of these viruses reviewed in Pipas and Levine, 2001 ). In addition to binding Rb and p53, TAg has been reported to bind β-catenin, resulting in β-catenin's stabilization, translocation into the nucleus and increased transactivation activity (Enam et al., 2002; Gan and Khalili, 2004) . TAg also modulates β-catenin stability and subcellular localization through Rac1 activation (Bhattacharyya and Khalili, 2007) . The regulation of cytosolic β-catenin is an essential step in the controlled functioning of the Wnt signaling cascade. Degradation of β-catenin is achieved by its phosphorylation at serine 45 by CK1α, and serine 33, serine 37 and threonine 41 by GSK3-β (Kimelman and Xu, 2006) . Phosphorylated β-catenin is recognized by beta-transducin-repeat containing protein (βTrCP), an F-box containing component of the Skp1-Cul1-F-box protein (SCF) E3 ubiquitin ligase complex, and targeted for ubiquitination and proteasomal degradation (Kimelman and Xu, 2006) . Additional βTrCP substrates include Wee1 (Watanabe et al., 2004) , Cdc25A and B (Busino et al., 2003; Kanemori et al., 2005) , IκB (Karin and Ben-Neriah, 2000) , and the tumor suppressors REST (Westbrook et al., 2008) and Pdcd4 (Dorrello et al., 2006) . βTrCP2 (also called HOS), is an F-box protein that exhibits 86% amino acid identity with βTrCP1; the two proteins only differ in their N-terminal sequences (Fuchs et al., 1999; Koike et al., 2000) . βTrCP2 also targets β-catenin and IκB for ubiquitination and proteasomal degradation, demonstrating an overlap of function for the two proteins (Fuchs et al., 1999) . Nonetheless, some differences in the two proteins have been recognized. For example, βTrCP2, but not βTrCP1, is essential for the ubiquitination, degradation and down-regulation of the interferon-α receptor (IFNAR1) (Kumar et al., 2003) and the prolactin receptor (PRLR) (Li et al., 2004) . The targeting of different substrates by the two F-box proteins may be attributed, in part, to differences in their subcellular localization; βTrCP1 resides primarily in the nucleus while βTrCP2 is found in the cytoplasm (Davis et al., 2002; Fuchs et al., 2004) .
βTrCP1 and βTrCP2 recognize most substrates via their phosphodegron consensus sequence, DpSGX 2-4 pS. Phosphorylation of the serine residues in this motif is required for βTrCP binding and for subsequent linkage to the ubiquitination machinery (Laney and Hochstrasser, 1999) . We have identified a potential phosphodegron at the C-terminus of JCV TAg (amino acids 639-645: DSGHGSS). In this study we have examined and characterized the interaction that occurs between JCV TAg and βTrCP, and investigated whether this interaction alters the amount of β-catenin, a βTrCP substrate, found in mammalian cells.
Results

JCV TAg interacts with βTrCP1
The multifunctional JCV TAg induces transformation of cells by interacting with key cellular proteins involved in cell cycle regulation and signal transduction. By scanning the primary sequence, we identified a potential βTrCP binding domain at the C-terminus of TAg (amino acids 639-645: DSGHGSS). To determine whether TAg interacts with βTrCP1, we performed GST pull down experiments with extracts of U87MG cells co-transfected with pCMV-JCV E or pCMV-T + /t − /T′ − , and plasmids expressing either wild type (WT) GST-βTrCP1 or mutant GST-βTrCPΔF. βTrCPΔF, a dominant negative form of βTrCP1, is missing the F-box domain required for its interaction with components of the SCF complex (Westbrook et al., 2008) . Because βTrCP1 targets its substrates for ubiquitination and degradation in the proteasome, we examined the integrity of the viral tumor proteins in cell extracts containing GST-βTrCP1 (Fig. 1A) . The TAg expression level did not vary detectably in the presence of βTrCP1, suggesting that the stability of TAg is not altered in the presence of the F-box protein. We also analyzed the expression levels of the GST-tagged βTrCP1 and βTrCPΔF, and noticed that the level of the mutant protein was consistently higher than that of WT βTrCP1 (Fig. 1B) . In addition, protein bands ranging in size from 26 to 34 kDa and recognized by the anti-GST antibody were detected on the Western blot (WB). These small peptides may result from partial degradation of GST-βTrCP1, and deletion of the F-box domain might confer increased stability to the βTrCPΔF protein. The GST pull down assay (Fig. 1C) indicated that TAg, and no other T protein, binds both βTrCP1 and βTrCPΔF in the presence (lanes 6, 8; respectively) or absence (lanes 7, 9; respectively) of the other 4 early tumor proteins. Because TAg interacts with βTrCPΔF (lanes 8, 9), which is unable to interact with the other components of the SCF complex, we conclude the interaction between TAg and the F-box protein is direct and does not occur through other members of the E3 ubiquitin ligase complex.
SV40 TAg does not interact with βTrCP1
The JCV and SV40 TAg sequences share 72% sequence identity (Frisque and White, 1992) , therefore we compared the primary sequence of SV40 TAg with that of JCV TAg to determine if SV40 TAg also possesses a βTrCP1 binding site. The C-terminus of SV40 TAg contains the related sequence DSGHETG (amino acids 656-662). The threonine at position 661 corresponds to serine 644 in the JCV TAg. Bora, an essential mitotic protein involved in spindle formation, is a known βTrCP1 target; it also has a threonine replacing the second serine of the binding motif (Seki et al., 2008) .
293T cells express SV40 early proteins and have been used in a number of βTrCP1 studies (Dorrello et al., 2006; Kitagawa et al., 1999; Sadot et al., 2000; Westbrook et al., 2008; Winston et al., 1999) . If SV40 TAg did bind βTrCP1, such an interaction would likely influence interpretations of data obtained in earlier studies. We performed GST pull down experiments with extracts from 293T cells transfected with the GST-βTrCP1 or GST-βTrCPΔF expressing constructs, or with extracts from the parental 293 cells co-transfected with pCMV-JCV E and either the GST-βTrCP1 or GST-βTrCPΔF plasmid. WB analyses demonstrated the presence of JCV and SV40 TAgs in 293 and 293T cells, respectively ( Fig. 2A) , and of GST-βTrCP proteins in both cell lines (Fig. 2B) . The GST pull down analyses indicated that the SV40 TAg in 293T cells does not interact with βTrCP1 nor βTrCPΔF (Fig. 2C , lanes 9, 11; respectively), whereas JCV TAg binds both proteins in 293 cells (Fig. 2C, lanes 8, 10) .
These experiments were also performed in Cos-7 cells, an African green monkey kidney line transformed by an origin-defective mutant of SV40 (Gluzman, 1981) , and again no binding was detected between SV40 TAg and βTrCP1 (data not shown).
Phosphorylation is required for the TAg-βTrCP1 interaction βTrCP1 recognizes its target proteins through a phosphodegron with the consensus sequence DSpGX 2-4 Sp, where both serine residues are plasmids were subjected to IP or GST pull down analyses. (A) Cell extracts (50 μg) were immunoprecipitated with anti-T antibody (PAb962) and the viral proteins were detected using an anti-T antibody cocktail. (B) Protein extracts (500 g) were analyzed for the expression of GST, GST-βTrCP1 and GST-βTrCPΔF by GST pull down and detection with an anti-GST antibody. (C) The interactions of TAg with βTrCP1 and βTrCPΔF were detected by performing GST pull downs of cell extracts (500 μg) and immunoblotting with an anti-T antibody cocktail (lanes 1, 4-9). Cell extracts (30 μg) containing either TAg or all five JCV early proteins (JCV E ) were immunoprecipitated with PAb962 followed by WB with an anti-T antibody cocktail (lanes 2, 3). Mock-transfected U87MG cells were used as a control (Con). Small proteins recognized by the anti-GST antibody are marked with two asterisks.
phosphorylated (Laney and Hochstrasser, 1999) . The JCV TAg domain predicted to interact with βTrCP1, (DSGHGSS), contains three potentially phosphorylatable serine residues. To examine if phosphorylation is required for βTrCP1-TAg binding, we transfected 293 cells with pCMV-JCV E , and 293T cells with either GST-βTrCP1 or GST-βTrCPΔF.
Since the endogenous SV40 TAg in 293T cells does not interact with βTrCP1 ( Fig. 2) , we chose these cells to express GST-βTrCP1 and GST-βTrCPΔF. The expression plasmids for the GST-tagged proteins contain the SV40 origin of replication, therefore, their transfection into TAg-producing cells leads to amplification of the vector and high levels of βTrCP1 and βTrCPΔF expression. Phosphatase treatment of 293 cell extracts containing the JCV tumor proteins resulted in the dephosphorylation of the T proteins, as evidenced by the enhanced mobility of the T′ proteins on the blot (Fig. 3A) . These 293 cell extracts, with or without phosphatase treatment, were combined with extracts from 293T cells expressing GST-βTrCP1 or GST-βTrCPΔF ( Fig. 3B) , and subjected to GST pull down analyses. Phosphatase treatment of the extracts containing the T proteins greatly reduced the interaction of TAg with βTrCP1 and βTrCPΔF ( Fig. 3C , lanes 8, 9; respectively), demonstrating that phosphorylation of TAg is required for the interaction between the viral and cellular proteins.
Serine 640 in the JCV TAg is essential for binding βTrCP1
The two serines in the destruction motif of known βTrCP1 substrates must be phosphorylated for recognition by the F-box protein (Cardozo and Pagano, 2004) . To identify the serine residue(s) in the JCV TAg destruction motif required for binding βTrCP1, we substituted each serine, either singly or in combination (Fig. 4) , with alanine (e.g., Ser640 to Ala; S640A) and examined the ability of the mutant TAgs to interact with βTrCP1. U87MG cells were co-transfected with the GST-βTrCP1 or GST-βTrCPΔF expression plasmids and pCMV-JCV E constructs expressing either WT or mutant TAg. Equivalent expression levels of the WT and mutant T proteins in U87MG cells suggest the mutations do not affect the stability of any of the viral tumor proteins (Figs. 4A, B, E, F). Western blots demonstrated the expression of the GST tagged βTrCP proteins (Figs. 4C, G). GST pull down analyses indicated that mutation of serine 640 severely reduces the interaction of TAg with βTrCP1 and βTrCPΔF Fig. 2 . SV40 TAg does not interact with βTrCP1. Extracts of 293 and 293T cells expressing GST, GST-βTrCP1 or GST-βTrCPΔF (GST-ΔF), and either JCV or SV40 early proteins, respectively, were subjected to IP or GST pull down analyses. (A) Extracts (50 μg) of 293T cells or 293 cells transfected with the JCV E -expressing vector were immunoprecipitated with a mixture of PAb416 and PAb419 (anti-SV40 T) antibodies or PAb962 and immunoblotted with a mixture of anti-T antibodies that recognize both JCV and SV40 tumor proteins. (B) GST pull down assays were performed on extracts (500 μg) of 293 and 293T cells, and GST, GST-βTrCP1 and GST-βTrCPΔF were detected by WB using anti-GST antibody. (C) Extracts (500 μg) of 293 and 293T cells were examined for interactions of JCV and SV40 TAgs with GST-βTrCP1 and GST-βTrCPΔF using GST pull down analyses, and immunoblotting with a mixture of anti-T antibodies (lanes 1, 4-11). Levels of JCV and SV40 TAg in the cell lines were examined by IP of cell extracts (15 μg) using anti-JCV or -SV40 TAg antibodies and WB with the mixture of anti-T antibodies (lanes 2, 3). Small proteins recognized by the anti-GST antibody are marked with two asterisks. Fig. 3 . Phosphatase treatment abolishes the TAg-βTrCP1 interaction. 293 cells were transfected with pCMV-JCV E , and 293T cells were transfected with vectors expressing GST, GST-βTrCP1 or GST-βTrCPΔF (GST-ΔF). Extracts of 293 cells expressing the T proteins were either treated 72 h p. t. with λ phosphatase (λPP) or left untreated. (A) 293 cell extracts (50 μg) expressing the T proteins were either treated with λ phosphatase or left untreated and then immunoprecipitated with an anti-T antibody. T proteins were detected by WB with a cocktail of anti-T antibodies. (B) Cell extracts (600 μg) were subjected to GST-pull down analysis and the GST-tagged proteins in 293T cells were detected with anti-GST antibody. (C) λ phosphatase treated or untreated 293 cell extracts (600 μg) containing the T proteins were mixed and incubated with extracts from 293T cells (600 μg) expressing GST-βTrCP1 or GST-βTrCPΔF. Binding analyses of TAg to GST beads (lane 1), 6, 8) and 7, 9) were performed by the GST pull down method. 293 cell extract (30 μg) containing TAg was immunoprecipitated with PAb962 as a marker (lane 10), and 293T cell extracts containing the GST tagged proteins (600 μg) were subjected to GST-pull down as controls (lanes 2, 3). Bound TAg was detected with a cocktail of anti-T antibodies. Phosphatase treatment greatly reduced the TAg-βTrCP interaction (lanes 8, 9). Fig. 4 . Amino acids serine 640 and 644 influence TAg binding to βTrCP1. pCMV-JCV E constructs carrying TAg single point mutations S640A, S644A, S645A, or double point mutations S640A-S644A, S640A-S645A or S644A-S645A, and GST, GST-βTrCP1 or GST-βTrCPΔF (GST-ΔF) were co-transfected into U87MG cells, and extracts were collected 72 h p. t. for IP and GST pull down analyses. (A, E) Expression levels of the WT, single and double mutant T antigens were analyzed using extracts (50 μg) immunoprecipitated with PAb962. The T proteins in cells expressing GST-βTrCP1 (A, E), or GST-βTrCPΔF (B, F), were detected with a cocktail of anti-T antibodies. (C, G) GST pull down analysis of cell extracts (600 μg) was performed to analyze the expression levels of GST, GST-βTrCP1 and GST-βTrCPΔF. The GST-tagged proteins were detected with α-GST antibody. (D, H) A GST pull down assay was performed on cell extracts (600 μg) and wild type or mutant TAgs bound to GST-βTrCP1 (D, lanes 4-7; H, lanes 4-8) and GST-βTrCPΔF (D, lanes 8-11; H, 9-13) were detected by WB with a cocktail of anti-T antibodies. Mutation of serine 640 of JCV TAg greatly reduced the TAg-βTrCP interaction (D, lanes 5, 9). Double mutant constructs containing a mutation at serine 640 of JCV TAg also greatly reduced the TAg-βTrCP interaction (lanes 5-7, 10-12) (H). U87MG cell extracts (30 μg) containing WT JCV E were immunoprecipitated with PAb962 as a size marker (D and H, lane 2). Mock-transfected U87MG cells were used as a control (Con) (D and H, lane 1). Small proteins recognized by the anti-GST antibody are marked with two asterisks. (Fig. 4D, lanes 5, 9; Fig. 4H, lanes 5-7, 10-12 ), while mutations of serines 644 and 645 do not (Fig. 4D, lanes 6 , 7, 10, 11; Fig. 4H, lanes 8, 13) . We did note; however, that mutant S644A consistently exhibited slightly reduced binding to βTrCP1 and βTrCPΔF (Fig. 4D, lanes 6, 10) . These data indicate that serine 640, and to a much lesser extent, serine 644, are involved in the interaction between TAg and βTrCP1.
TAg interacts with βTrCP2 βTrCP2 shares 86% amino acid identity with βTrCP1, and both proteins recognize the phosphodegron, found in several common substrates, that contains the sequence DSpGX 2-4 Sp. However, the two proteins do exhibit functional differences, including the recognition of unique cellular targets and different subcellular localization patterns (Kumar et al., 2003; Li et al., 2004) . βTrCP1 is mainly found in the nucleus, whereas βTrCP2 localizes to the cytoplasm, suggesting that βTrCP1 promotes degradation of nuclear substrates, and βTrCP2 targets cytoplasmic substrates. Since some cellular targets, such as β-catenin or IkB, as well as the HIV viral protein Vpu, are known to interact with both βTrCP1 and βTrCP2 (Fuchs et al., 1999; Mangeat et al., 2009 ), we determined whether TAg binds βTrCP2 by performing GST pull down analyses on cell extracts expressing GST βTrCP2 and either WT or mutant TAg. WB analyses demonstrating the expression levels of the T proteins (Fig. 5A) , and the GST-tagged βTrCP1 and βTrCP2 (Fig. 5B ) are shown. Our GST pull down analysis confirmed that TAg interacts with βTrCP2 (Fig. 5C , lane 6), and that serine 640 of TAg is required for this binding (Fig. 5C, lane 8) .
TAg co-localizes with βTrCP1 and βTrCP2 in the cytoplasm βTrCP1 and polyomavirus TAgs are found predominantly in the nucleus, although a small percentage of these proteins is detected in the cytoplasm (Davis et al., 2002; Soule and Butel, 1979) . βTrCP2 is mainly a cytoplasmic protein (Davis et al., 2002) . To determine if TAg and βTrCP1 or βTrCP2 co-localize in the cell, double immunofluorescence staining was performed. U87MG cells were co-transfected with pCMV-T + /t − /T′ − and either the GST-βTrCP1 or GST-βTrCP2 plasmids. Cells were stained with antibodies directed against the T protein or GST, and the subcellular localization of the viral or GST-tagged protein was analyzed by confocal microscopy. As expected, nuclear fluorescence predominated in cells expressing JCV TAg in the absence of GST-βTrCP1 (Fig. 6A ) and in cells expressing GST-βTrCP1 in the absence of TAg (Fig. 6B) . Some cytoplasmic staining could be detected in the latter case. Cytoplasmic fluorescence was detected exclusively in cells expressing GST-βTrCP2 in the absence of TAg as reported (Davis et al., 2002) (Fig. 6D) . When TAg and GST-βTrCP1 were co-expressed, the majority of cells exhibited TAg staining in both the nucleus and cytoplasm, and the two proteins co-localized in the cytoplasm (Fig. 6C) . When TAg and βTrCP2 were expressed together, co-localization was exclusively cytoplasmic, and TAg staining was observed in both nuclear and cytoplasmic compartments (Fig. 6E) . Similarly, we analyzed the subcellular co-localization of TAg in the presence of βTrCPΔF, which lacks the F-box domain. Deletion of the F box inhibits the ability of βTrCP to interact with the components of the degradation complex Skp1, Cul1 and Roc1. While still capable of interacting with its target proteins, βTrCPΔF can no longer degrade them. As expected, βTrCPΔF localizes in the nucleus when expressed independently (Sadot et al., 2000) (Fig. 6F) . Interestingly, when TAg and βTrCPΔF were co-expressed, the two proteins co-localized only in the cell nucleus, and no cytoplasmic fluorescence was detected for TAg (Fig. 6G) , suggesting that the cytoplasmic localization of TAg depends on βTrCP and βTrCP's ability to interact with other members of the SCF complex. This data also suggests βTrCP must interact with members of the SCF complex to induce its proper cytoplasmic translocation. Similar results were obtained in three independent experiments in which more than 100 individual cells were examined.
The TAg-βTrCP interaction does not significantly affect the levels of the βTrCP substrate β-catenin β-catenin is one of several cellular proteins targeted for degradation by SCF βTrCP , and its recognition as a substrate requires phosphorylation of serines 33 and 37 residing within the phosphodegron bound by βTrCP (Kimelman and Xu, 2006) . TAg has been reported to interact with β-catenin and to promote its stabilization (Gan and Khalili, 2004) . We hypothesized that this TAg function might be mediated through its interaction with βTrCP. U87MG cells were transfected with pCMV-JCV E , or pCMV-JCV E constructs encoding the S640A, S644A or S645A mutant Fig. 5 . JCV TAg interacts with βTrCP2. U87MG cells were co-transfected with pCMV-JCV E or the pCMV-JCV E construct carrying the TAg point mutation S640A, and GST, GST-βTrCP1 or GST-βTrCP2 plasmids. Cell extracts were prepared 72 h p. t. for IP and GST pull down analyses. (A) Cell extracts (50 μg) were immunoprecipitated with anti-T antibody (PAb962) and viral proteins were visualized by WB, using an anti-T antibody cocktail. (B) Extracts (500 g) were analyzed for the expression of GST, GST-βTrCP1 and GST-βTrCP2 using the GST pull down assay followed by WB with an anti-GST antibody. (C) The interactions of WT and mutant TAg with βTrCP2 were detected by performing GST pull downs of cell extracts (500 μg) and immunoblotting with an anti-T antibody cocktail (lanes 1, 4-8). Cell extracts (30 μg) containing WT TAg and mutant TAg were immunoprecipitated with PAb962 followed by WB with an anti-T antibody cocktail (lanes 2, 3). Mock-transfected U87MG cells were used as a control (Con; lane 1). Small proteins recognized by the anti-GST antibody are marked with two asterisks.
TAgs, and TAg and β-catenin levels were examined by WB analysis (Figs. 7A, B) . We observed, as predicted, that endogenous β-catenin levels in cells expressing the S640A mutant TAg were similar to those found in untransfected cells (Fig. 7B, lane 3 vs. 1 ). However, in cells producing WT TAg, we did not observe a significant elevation of β-catenin (Fig. 7B, lane 2) . Similar results were obtained when the experiment was repeated in PHFG cells or the human colon cancer cell line RKO, and with vectors expressing exogenous myc-tagged β-catenin (data not shown). These data fail to support our prediction that JCV TAg stabilizes β-catenin by interfering with βTrCP-induced degradation, since i) the inability of mutant TAg to bind βTrCP does not result in decreased levels of β-catenin relative to that measured using WT TAg and ii) we were unable to confirm the earlier report that TAg stabilizes β-catenin (Gan and Khalili, 2004) , an observation upon which our hypothesis was formulated.
Discussion
Our study reveals a new activity for JCV TAg that links this tumor protein to the SCF βTrCP1/2 destruction machinery. Interestingly, a potential βTrCP recognition domain is also present in the TAgs of the human BK and Merkel cell polyomaviruses (amino acids 640-646; amino acids 811-817), respectively, but not in two other recently discovered human polyomaviruses, KIV and WUV. Viruses have developed strategies to hijack key cellular processes to initiate their own replication cycles. Recently, much attention has focused upon the ability of tumor viruses to interfere with a cell's ubiquitination and degradation systems (Shackelford and Pagano, 2004) . Welcker and Clurman (2005) described a phosphorylation-dependent interaction of SV40 TAg with the F-box protein, Fbw7, the substrate recognition subunit of the SCF Fbw7 ubiquitin ligase complex. This interaction decreases the turnover of at least one known SCF Fbw7 substrate, cyclin E, resulting in enhanced activity of cyclinE-Cdk2 kinase (Welcker and Clurman, 2005) . SV40 TAg has also been found to interact with Cul7, a subunit of a SCF-like E3 ligase complex (Ali et al., 2004; Kasper et al., 2005; Kohrman and Imperiale, 1992) . Cul7 interacts with Fbwx8, Roc1
and Skp1 (Ali et al., 2004; Kasper et al., 2005) to target the ubiquitination and degradation of cyclin D1 and IRS-1 (Okabe et al., 2006; Xu et al., 2008) . TAg mutations that abolish Cul7 binding result in a transformation-defective virus. Tumor proteins of the human papillomaviruses, HPV-16 and -18, also facilitate proteasomal degradation of cellular proteins. The E6 protein of these high risk HPV types recruits the cellular ubiquitin ligase, E6-associated protein (E6AP) (Howley, 2006) . The E6-E6AP complex interacts with p53 to promote the polyubiquitination and degradation of this tumor suppressor. This event reveals a mechanism whereby a viral protein facilitates the recognition of a new target substrate by an ubiquitin ligase complex. A second HPV tumor protein, E7, targets pRB and recruits the ubiquitin conjugating enzyme, E2-25K, resulting in the degradation of this tumor suppressor (Howley, 2006; Oh et al., 2010) .
βTrCP has been shown to be a cellular target of HIV (Besnard-Guerin et al., 2004; Bour et al., 2001; Estrabaud et al., 2007; Margottin et al., 1998) . The HIV Vpu protein acts as pseudo-substrate by interacting with βTrCP1 and bringing the degradation machinery in close proximity to substrates that include the CD4 receptor. This bridging action of Vpu results in recognition of CD4 by βTrCP1 and the proteasomal destruction of the T cell receptor (Margottin et al., 1998) . The CD4 sequence does not contain the βTrCP1 consensus motif, suggesting that Vpu promotes βTrCP1 recognition and degradation of a new substrate. In contrast, the Vpu-βTrCP1 interaction inhibits the degradation of some authentic βTrCP1 substrates, such as β-catenin, ATF4, IkB and CdC25A (Besnard-Guerin et al., 2004; Bour et al., 2001; Estrabaud et al., 2007) . Further, Emi1, yet another βTrCP1 substrate, remains unaffected by the Vpu-βTrCP1 interaction. These findings indicate that Vpu directs βTrCP1 to multiple substrates that may be differentially affected by each interaction (Estrabaud et al., 2007) .
In this study we found that JCV TAg, but not the related SV40 TAg, binds to βTrCP1 and βTrCP2, and that this interaction is phosphorylation dependent. Binding requires a destruction motif within the C-terminus of TAg that includes a serine residue at position 640. A second serine at position 644 appears to make a small contribution to TAg-βTrCP1bind-ing. The observation that just one serine within the destruction motif is required for βTrCP binding highlights a difference between TAg and other known βTrCP substrates for which two phosphorylated serines are required (Cardozo and Pagano, 2004) . In addition, JCV TAg stability was not altered detectably by its interaction with the F-box protein, suggesting TAg acts as a pseudo-substrate (Margottin et al., 1998) , bringing βTrCP in close proximity to potential target proteins without being degraded itself.
Our immunofluorescence data indicate that TAg and βTrCP co-localize when expressed in the same cell. The polyomavirus TAgs have a strong nuclear localization signal and are predominantly found in the nucleus; only a small amount of TAg is found in the cytoplasm (Soule and Butel, 1979) . Subcellular localization of βTrCP1 and βTrCP2 has been detected in the nucleus and cytoplasm, respectively (Davis et al., 2002; Fuchs et al., 1999) , and our results support this observation. Upon overexpression of βTrCP in cells, TAg staining became readily apparent in the cytoplasm. Additionally, while βTrCP2 remains cytoplasmic in the presence of TAg, significant βTrCP1 staining is redirected from the nucleus to the cytoplasm, where the cellular and viral proteins co-localize. The relocalization of TAg and βTrCP1 to the cytoplasm might be substratedependant. It has been shown that the nucleo-cytoplasmic shuttling of βTrCP1 is regulated by its nuclear binding to the pseudo-substrate, hnRNP-U. High affinity βTrCP1 substrates compete with hnRNP-U for binding, leading to the release of active βTrCP1 that may then target nuclear or cytoplasmic targets for subsequent degradation (Davis et al., 2002; Fuchs et al., 2004) . The co-localization of TAg and βTrCP1 in the cytoplasmic compartment might indicate that TAg successfully competes with hnRNP-U in the nucleus for βTrCP1 binding, resulting in the cytoplasmic localization of the two proteins and subsequent degradation of a targeted substrate (Davis et al., 2002) .
F-box proteins, including βTrCP, are characterized by the presence of two conserved regions; the WD repeats, which are essential for Cell extracts (30 μg) were subjected to WB, and endogenous β-catenin was detected with an anti-β-catenin antibody. Lane 1 shows the endogenous levels of β-catenin in cells transfected with pCR3 vector as a control. Endogenous β-catenin levels in the presence of WT or mutant TAgs correspond to lanes 2 through 5. The blots were stripped and reprobed for β-actin with anti-β-actin antibody as a loading control. Relative differences in β-catenin levels between extracts were determined by normalizing β-catenin values to actin levels using the ImageJ program. Based upon these calculations, a value of 1.0 was arbitrarily assigned to JCV E -transfected cells. The relative β-catenin levels observed in cells expressing the S640A was 0.9 (B, lane 3).
recognition of the targeted substrates, and the F-box domain, which enables βTrCP to interact with Skp1, Cul1 and Roc1 . We detected βTrCPΔF, as well as βTrCP1, in the nuclear compartment as already reported (Sadot et al., 2000) . Our immunofluorescence data show that TAg and βTrCPΔF, co-localize exclusively in the nucleus. It is noteworthy that no cytoplasmic relocalization of TAg was detected in cells expressing βTrCPΔF. The SCF complex members Cul1, Skp1 and Roc1 are detected in both the nucleus and cytoplasm, and it is suggested that their recruitment to the nucleus occurs upon activation of the SCF complex (Andrews et al., 2006; Boyer et al., 2004; Furukawa et al., 2000) . Our data suggest that the cytoplasmic localization of TAg in the presence of βTrCP requires a functional SCF βTrCP complex. This observation, together with the finding demonstrating cytoplasmic relocalization of βTrCP1and TAg, point to the possibility that the cytoplasmic shuttling of the proteins requires βTrCP to interact, not only with its substrates as already proposed (Davis et al., 2002) , but also with the other members of the degradation complex. TAg has been reported to stabilize β-catenin, a known βTrCP1 substrate (Bhattacharyya and Khalili, 2007; Gan and Khalili, 2004; Kimelman and Xu, 2006) , therefore we investigated whether TAg binding to βTrCP influences β-catenin stability. As previously reported (Gan and Khalili, 2004) , an interaction between TAg and endogenous β-catenin was detected (data not shown). However, only minor differences in the levels of β-catenin were detected in cells expressing WT vs. the mutant S640A TAg. We are unable to explain the discrepancy between our results and those previously reported (Bhattacharyya and Khalili, 2007; Gan and Khalili, 2004) ; however, our data indicate that if TAg does stabilize this critical component of the Wnt pathway, it is not due to its ability to block βTrCP function.
β-catenin, has been identified as an important target in the process of TAg-induced cellular transformation. Other targets potentially affected by the TAg-βTrCP interaction remain to be explored. In addition to their influence upon the G1/S phase transition of the cell cycle, polyomaviruses promote cell cycle arrest at the G2/M phase (Davy and Doorbar, 2007) . JCV TAg induces G2 arrest as a result of the activation of the ATM and ATR checkpoint pathways, thereby promoting viral replication in permissive cells (Orba et al., 2010) . βTrCP1 is a key player in the S and G2 DNA damage checkpoint pathways, and it promotes cell cycle arrest following DNA damage by attenuating CDK1 activity through degradation of Cdc25A. Additionally, βTrCP1 has been shown to restore cell cycle progression and entry into mitosis by facilitating the degradation of claspin and WEE1 (Branzei and Foiani, 2008) . One might speculate that the TAg-βTrCP1 interaction contributes to one or more of these cell cycle events.
We have identified for the first time a link between JCV TAg function and a mechanism of proteasome degradation in the cell. We have not yet identified a target affected by the TAg-βTrCP interaction; however, preliminary data in our laboratory reveal that mutation of serine 640 within TAg's destruction motif significantly reduces JCV replication late in infection (Reviriego-Mendoza and Frisque, unpublished data) . This finding highlights a potential function of βTrCP in the JCV life cycle. Given the oncogenic potential of JCV and the increasing evidence of the involvement of the ubiquitin proteasomal pathways in cell growth and transformation (Frescas and Pagano, 2008; Fuchs et al., 2004) , it will be important to identify the cellular proteins targeted by the JCV TAg-βTrCP interaction to better understand the oncogenic and pathogenic potential of this human polyomavirus.
Materials and methods
DNA constructs
The pCMV-JCV E vector, which expresses the JCV early coding region, and the pCMV-T + /t − /T′ − vector, which expresses TAg only, were described earlier (Bollag et al., 2006 (Bollag et al., , 2010 . The single mutants pCMV-JCV E (S640A), pCMV-JCV E (S644A) and pCMV-JCV E (S645A) and the double mutants pCMV-JCV E (S640A-S644A), pCMV-JCV E (S640A-S645A) and pCMV-JCV E (S644A-S645A) were created by PCR-based site-directed mutagenesis with primers identified in Table 1 . The pDEST27, pGSTβTrCP1, pGST-βTrCP2 and pGST-βTrCPΔF constructs were gifts from Dr. Wade Harper (Westbrook et al., 2008) .
Cells, extracts and DNA transfections U87MG cells were grown in minimum essential Eagle's medium (MEM) supplemented with 10% fetal bovine serum (FBS), 2% sodium pyruvate, 1% essential amino acids, 2 mM L-glutamine, penicillin G (100 U/ml) and streptomycin (100 μg/ml). The human embryonic kidney cell lines 293 and 293T cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% FBS, L-glutamine, penicillin G (100 U/ml) and streptomycin (100 μg/ml). U87MG cells were incubated at 37°C in 10% CO 2 , and 293, 293T cells were incubated at 37°C in 5% CO 2 .
Transient transfections and co-transfections were carried out with lipofectamine 2000 following the manufacturer's instructions (Invitrogen, Carlsbad, CA). Briefly, 5×10 5 cells were plated on 60 mm tissue culture plates, and transfected 24 h after seeding with 1 μg (8 μg for the detection of endogenous β-catenin) of each of the DNA constructs. Cell extracts prepared as previously described (Bollag, et al., 2006) , were obtained 72 h post-transfection (p.t.) for binding analyses, and 48 h p.t. for the detection of endogenous β-catenin. a Single point mutations in the destruction motif (primers 1-6) were introduced into pCMV-JCV E . Serines 640 (primers 1and 2), 644 (primers 3 and 4) and 645 (primers 5 and 6) were changed to alanine (altered nucleotides are in bold). Double point mutations (primers 7 to 12) were produced by using single mutant pCMV-JCV E (S640A) as a template to create the double mutant S640A-S644A (primers 7, 8), and single mutant pCMV-JCV E (S645A) as a template to create the double mutants S640A-S645A (primers 9, 10) and S644A-S645A (primers 11, 12). New altered nucleotides are in bold and pre-existing mutations are underlined. b Nucleotide numbers are based upon the JCV(Mad1) sequence (Frisque et al., 1984) .
Antibodies
Monoclonal anti-T antibodies PAb962, PAb2000, PAb2001, PAb2003, PAb2024 and PAb2030 (Bollag and Frisque, 1992; Bollag et al., 2000; Tevethia et al., 1992) were used to detect JCV tumor proteins. PAb416 and PAb419 were used to detect SV40 T proteins (Harlow et al., 1981) . GST-tagged proteins and β-actin were detected with rabbit anti-GST antibody (1:5000) and anti-β-actin (1:5000) (Sigma-Aldrich, St. Louis, MO), respectively. Mouse anti-β-catenin (E-5) (1:300) (Santa Cruz Biotechnologies, Santa Cruz, CA) was used to detect endogenous β-catenin. Protein bands were visualized with secondary antibodies conjugated to either alkaline phosphatase (Sigma) or horseradish peroxidase (Cell Signaling Technology, Danvers, MA).
Immunoprecipitation and GST pull down experiments
The detection of the T proteins was performed by immunoprecipitation (IP) as described earlier (Bollag et al., 2006) . GST pull down assays to detect GST-tagged βTrCP1, GST-βTrCP2 and βTrCPΔF, and to analyze βTrCP-TAg interactions were described elsewhere (Westbrook et al., 2008) .
Phosphatase treatment
λ-phosphatase treatment of 293 cell extracts was performed according to the manufacturer's instructions (New England Biolabs, Ipswich, MA). 293 cells transfected with pCMV-JCV E were lysed 72 h p.t. with EBC lysis buffer (50 mM Tris, pH 8.0, 120 mM NaCl, 0.5% NP-40) supplemented with protease inhibitors (2 μg/ml leupeptin, 2 μg/ml E-64, 1 μg/ml aprotinin and 0.25 mM pefabloc). Extracts were treated with λ-phosphatase for 25 min at 30°C. The reaction was terminated by adding 10 mM Na 3 VO 4 and 50 mM NaF.
Immunofluorescence staining U87MG cells (3.5 × 10 5 ) were seeded on coverslips. After 48 h p.t., cells grown on coverslips were fixed with 4% paraformaldehyde for 20 min, and permeabilized with 0.02% Triton X-100 for 5 min. Cells were incubated with blocking solution (10% heat-inactivated goat serum) (Millipore, Billerica, MA) for 45 min. Subsequently, cells were incubated with a cocktail of anti-T antibodies (PAb962, PAb2001, PAb2003, PAb2024 and PAb2030; 1:250) for 1 h. Cells were washed with PBS and incubated for 30 min with goat anti-mouse Alexa Fluor 594 (1:1000) (Invitrogen). Cells were washed with PBS and incubated with blocking solution for 45 min prior to incubating with mouse anti-GST antibody (1:2000). Goat anti-mouse Alexa Fluor 488 (1:1000) (Invitrogen) was used as a secondary antibody. Double and single immunostainings were performed on cells that did not express TAg nor GST-βTrCP (negative controls; data not shown). Immunostained cells were viewed under a confocal microscope (Olympus FV1000 Laser Scanning Confocal Microscope, Inverted Olympus IX-81. Cytometry Facility, Huck Institutes of the Life Sciences, Penn State University), using the FV10-ASW version 1.7 analyzing software. Sequential scans were used for all images.
